Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus as Second-line Therapy for Autoimmune Hepatitis (Pilot Study)
jRCTs061180063Completed
- Start
- Oct 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus in autoimmune hepatitis (AIH). Primary endpoints: ALT normalization at 2 weeks, Duration of ALT normalization within first 2 weeks and 4 more. Started Oct 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on jRCTs061180063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180063.